Adalvo is pleased to announce the successful DCP submission for Bosutinib 100, 400, 500mg film-coated tablets, indicated for the treatment of Chronic Myelogenous Leukemia.
In 2022, this product achieved global sales of $603M, demonstrating a 3-year CAGR of 10% according to IQVIA.
Dedicated to advancing our oncology portfolio, Adalvo offers a diverse range of dossiers to support our partners in overcoming various challenges. This accomplishment marks a significant step forward in our commitment to providing impactful solutions in the field of oncology.
Our oncology dossiers include, but are not limited to:
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Reach out to your preferred Business Partner below to access Adalvo's Oncology dossiers.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!